InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.185 -0.205 (-52.56%)+
Announcement
Release
15 Oct 2025 8:33AM
Price at Release
$0.390
Full Release
download
Summary
Proteomics International Laboratories Ltd has expanded its collaboration with the University of Melbourne and the Royal Women’s Hospital to advance the PromarkerEndo blood test for diagnosing endometriosis. This agreement focuses on further validating the diagnostic tool and developing tissue-specific biomarkers to enhance the test's capability. Endometriosis affects one in nine women worldwide, with an average diagnosis time of seven years, highlighting the need for this non-invasive test. The collaboration grants Proteomics International exclusive rights to commercialize any jointly-owned intellectual property resulting from this project. The PromarkerEndo test, designed to detect protein biomarkers in the blood, promises a quicker and more cost-effective diagnosis compared to current surgical methods.
Key Points
  • PromarkerEndo blood test aims to diagnose endometriosis early.
  • Collaboration with University of Melbourne and Royal Women’s Hospital.
  • Endometriosis affects 1 in 9 women globally.
  • Diagnosis currently takes an average of 7 years.
  • New test hopes to reduce diagnostic delays.
  • Proteomics International holds exclusive license for commercialization.
  • Project includes developing next-generation tissue-specific test.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.